BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 136 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 136 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $271.33, for a total value of $36,900.88. Following the completion of the sale, the insider owned 36 shares in the company, valued at approximately $9,767.88. This represents a 79.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $263.61 on Thursday. The business’s 50 day moving average price is $301.03 and its 200 day moving average price is $315.60. The firm has a market cap of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ONC shares. Barclays upped their target price on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Leerink Partners upped their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Royal Bank Of Canada upped their target price on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Finally, Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Mariner LLC lifted its holdings in BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after acquiring an additional 32 shares during the period. Signaturefd LLC lifted its holdings in BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after acquiring an additional 33 shares during the period. Farther Finance Advisors LLC lifted its holdings in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after acquiring an additional 39 shares during the period. CWM LLC lifted its holdings in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the period. Finally, Benjamin Edwards Inc. lifted its holdings in BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after acquiring an additional 51 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.